Is the price fair?
What TFX's price assumes
Today's price asks for 12% free cash flow growth a year; over the last three years Teleflex Incorporated delivered −20%, the price is ahead of the record.
2.48
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.0%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; the business has delivered −20% a year over the last three.
- Price / book
- 1.71
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 1.71
- EV / EBIToperating margin 2.0%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 3.52
- Free cash flow, trailing twelve months
- $168M
- Market capitalisation
- $5.62B
- 3-year revenue growth
- −8.0%
- 3-year free cash flow growth
- −20%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #12 of 27 by Smart Score